Glycoengineered anti-CD20 type II monoclonal antibody inducing B‑cell depletion via enhanced ADCC and direct cell death.
Glycoengineered humanized type II anti-CD20 IgG1 that binds CD20 on B cells and depletes them via enhanced Fc gamma RIIIa-mediated ADCC and strong direct, caspase-independent cell death, with relatively limited CDC.
Obinutuzumab binds CD20 on B cells and induces strong direct, caspase-independent cell death (type II) and engages Fc gamma RIIIa on NK cells/macrophages to mediate ADCC; CDC is limited.
Investigational anti-HER2 monoclonal antibody intended to inhibit HER2 signaling and promote immune-mediated cytotoxicity (e.g., ADCC) in HER2-expressing tumors.
IAH0968 is an anti‑HER2 monoclonal antibody that binds HER2/ERBB2 on tumor cells, inhibits HER2 signaling (e.g., prevents receptor activation/dimerization), and promotes immune‑mediated killing via antibody‑dependent cellular cytotoxicity (ADCC), leading to death of HER2‑expressing cancer cells.
Anti-HER2 antibody binds HER2 on tumor cells and engages Fc receptor–bearing immune cells (e.g., NK cells) to mediate ADCC, killing HER2-expressing cells; also inhibits HER2 signaling.
Humanized monoclonal antibody targeting HER2, blocking signaling and mediating ADCC; used in the comparator arm with CAPEOX.
Humanized IgG1 monoclonal antibody that binds the extracellular domain of HER2 (ERBB2), blocking receptor dimerization and downstream signaling, promoting receptor internalization, and mediating antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
HER2+ cells are opsonized by trastuzumab and killed via Fc-mediated ADCC by NK cells (and other FcγR+ effectors); complement may contribute. Signaling blockade is antiproliferative rather than cytotoxic.
Ex vivo–manufactured, polyclonal TCR-mediated tumor antigen–specific CTLs expanded in G-Rex bioreactors to enrich early-memory phenotypes; administered as adoptive T-cell therapy targeting pediatric solid tumors.
Ex vivo–expanded, polyclonal cytotoxic T lymphocytes with native TCRs recognize shared tumor-associated antigens presented by HLA class I on pediatric solid tumor cells, become activated, and mediate perforin/granzyme-dependent killing with supportive cytokine secretion; enrichment for early-memory phenotypes enhances in vivo persistence and antitumor activity after adoptive transfer.
Adoptively transferred antigen-specific CTLs recognize the tumor antigen peptide presented by HLA class I via their native TCR and induce target-cell death via perforin/granzyme-mediated cytolysis (and Fas/FasL apoptosis).
Subcutaneous anti-CD38 monoclonal antibody that depletes CD38-positive plasma cells to reduce immunoglobulins and donor-specific anti-HLA antibodies.
Human IgG1-kappa anti-CD38 monoclonal antibody that binds CD38 on plasma cells and other CD38+ cells and induces cell depletion via ADCC, ADCP, and CDC, reducing immunoglobulins and donor-specific anti-HLA antibodies and modulating immunosuppressive cell subsets.
Anti-CD38 IgG1 binds CD38 on target cells and induces Fc-mediated ADCC (NK cells), complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis (ADCP), depleting CD38+ cells.